MDM2 and sarcoma: A second study explored the SEER database (The Surveillance, Epidemiology, and End Results) with respect to cardiac sarcoma presentation and outcome (no specific data were provided in terms of the age or sex ratio with respect to the intimal type) [28], while the third cohort included a re-do MDM2 exploration in terms of gene amplification, histological profile, and immunostaining (n = 20 patients with primary intimal sarcomas) [36].